---All---
  • ---All---
  • Accession
  • Catalog #

Topoisomerase-II Antibody (alpha) Phospho-pT1343Rabbit Monoclonal Antibody

Country
United States
Australia Austria Belgium Brazil Bulgaria Canada China Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Iceland India Indonesia Ireland Israel Italy Japan Korea Latvia Lithuania Luxembourg Macedonia Malaysia Malta Netherlands Norway Pakistan Poland Portugal Romania Serbia Singapore Slovakia Slovenia Spain Sweden Switzerland Taiwan Turkey United Kingdom United States Vietnam Others
Ordering Information
Catalog # Size Availability Price  
AJ1780b 100ul 400 ul 2-3 days $ 355.00 Add to cart
  • Specification
  • Citiations : 0
  • Reviews
  • Protocols
  • Backgrounds

Topoisomerase-II Antibody (alpha) Phospho-pT1343 - Product info

ApplicationWB, IHC
  • Applications Legend:
  • W=Western Blotting
  • IP=Immunoprecipitation
  • IHC-P=Immunohistochemistry (Paraffin)
  • IF-IC=Immunofluorescence (Immunocytochemistry)
  • F=Flow Cytometry
Primary AccessionP11388
ReactivityHuman
Clone NamesEP1054Y
Calculated MW174385 Da
Gene ID 7153
Other Names
TOP2A, TOP2, DNA topoisomerase 2-alpha, DNA topoisomerase II, alpha isozyme
Target/Specificity
A synthetic phospho-peptide corresponding to residues surrounding Thr 1343 of human Topo II alpha was used as immunogen. The antibody only detects Topo II alpha phosphorylated on Threonine 1343.
Dilution
WB~~1:1000
IHC~~1:100~250
Format
50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA.
Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Precautions
Topoisomerase-II Antibody (alpha) Phospho-pT1343 is for research use only and not for use in diagnostic or therapeutic procedures.

Topoisomerase-II Antibody (alpha) Phospho-pT1343 - Protein Information

Name TOP2A
Synonyms TOP2
Function
Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks. Essential during mitosis and meiosis for proper segregation of daughter chromosomes
Cellular Location
Cytoplasm. Nucleus, nucleoplasm. Note=Generally located in the nucleoplasm

Topoisomerase-II Antibody (alpha) Phospho-pT1343 - Related products

AP9248b: TOP2A Antibody (C-term)

RI15407: TOP2A predesign siRNA

BP9248b: TOP2A Antibody (C-term) Blocking Peptide

AT4305a: TOP2A Antibody (monoclonal) (M01)

AJ1780a: Topoisomerase-II Antibody

AJ1780b: Topoisomerase-II Antibody (alpha) Phospho-pT1343

AJ1780c: Topoisomerase-II Anttibody (alpha) Phospho-pS1106

Abgent welcomes feedback from its customers.

If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.

If you have any additional inquiries please email technical services at tech@abgent.com.

Thank you for your support.


Submit

Provided below are standard protocols that you may find useful for product applications.

BACKGROUND

DNA topoisomerase II alpha (Topo IIα) is a 170 kDa ubiquitous nuclear enzyme belonging to the topo family, which regulates the topological states of DNA. Topo II is required in chromatin condensation and segregation during mitosis. Topo II α is cell cycle regulated and its level peaks between G2 to M phase. It has been linked to cell proliferation and it may be the main isoform of Topo II involved mitotic processes (1). Topo II α passes one strand of DBA through a reversible break in a second DNA strand, which catalyzes the topological isomerisation of DNA during cell cycle (2). Topo II α overexpression has been linked to a number of human maligenacies and is the target for many chemotherapeutic agents. The majority of anticancer drugs targeting Topo IIα initiate apoptosis by stabilizing the convalent complex formed between DNA and Topo IIα (3).

REFERENCES

1. Ohasi Y, et al. Anticancer Res, 19:1873
2. Sakaguchi A, et al. J Cell Sci 117:1047-104, 2004.
3. Zhou Z, et al. Mol Cancer Res 3:271-275, 2005.